Not Signed In - [ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Speech and Communication Disorders |
|
|
Clinical Trial: Interactions Between Cocaine and Ethanol and Disulfiram - 1
This study is currently recruiting patients.
Purpose
The purpose of this study is to assess potential interactions between intravenous cocaine and ethanol and oral disulfiram.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Alcohol-Related Disorders Cocaine-Related Disorders | Drug: Disulfiram | Phase I |
MedlinePlus related topics: Cocaine Abuse; Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Placebo Control
Official Title: Interactions Between IV Cocaine and Ethanol and Oral Disulfiram
Expected Total Enrollment: 18
Study start: August 2004; Expected completion: July 2005
This is a two-site, double blind, placebo-controlled inpatient study to determine the cardiovascular and psychiatric safety of alcohol use in cocaine-dependent subjects who had used cocaine after treatment with disulfiram.
Eligibility
Ages Eligible for Study: 18 Years - 50 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Must meet DSM-4 criteria for cocaine abuse or dependence and are not seeking treatment.
- Ability to verbalize undertanding of consent form and provide written informed consent and verbalize willingness to complete study procedures; be able to comply with protocol requirements.
Exclusion Criteria:
- Please contact site for more information.
Location and Contact Information
California
UCLA Integrated Substance Abuse Program, Los Angeles, California, 90024, United States; Recruiting
Texas
University of Texas Hlth Sci Ctr San Ant, San Antonio, Texas, 78284 7828, United States; Recruiting
John Roache, Ph.D., Principal Investigator, University of Texas Health Sci Cntr, San Antonio
More Information
Record last reviewed: March 2005
Last Updated: March 24, 2005
Record first received: October 15, 2004
ClinicalTrials.gov Identifier: NCT00094289
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- American Speech-Language-Hearing Association
- Apraxia of Speech (National Institute on Deafness and Other Communication Disorders)
email this page
print this page
bookmark this page
feedback on this page
